Engineering the Next Generation of CAR T Therapy:
Dual target strategy; in vivo innovation
Pipeline
Tempest is a clinical-stage CAR-T company building the future of in vivo CAR-T therapy with broad potential benefit for patients with autoimmune diseases or cancer
News
October 14,
2026
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
September 23,
2026
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
September 15,
2026
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform